Citation: | WANGYue, CHENBin, LUWu-guang, CAIRui, XULiu-gang, HUANGDan, CAOPeng, SHENJian-ping, ZHOUQian. Protective Effect of Shikonin on Ach-CaCl2-Induced Atrial Fibrillation in Rats[J]. Journal of Nanjing University of traditional Chinese Medicine, 2020, 36(1): 78-82. |
[1] |
BORIANI G, DIEMBERGER I, MARTIGNANI C, et al. The epidemiological burden of atrial fibrillation: A challenge for clinicians and health care systems[J]. Eur Heart J, 2006, 27: 893-894.
|
[2] |
BALL J, CARRINGTON MJ, MCMURRAY JJV, et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century[J]. Int J Cardiol, 2013, 167: 1807-1824.
|
[3] |
徐永玄,杨萍,郭涛.房颤发生机制及治疗新进展[J]. 昆明医科大学学报,2019,40(5):135-138.
|
[4] |
DA SILVA. Influence of inflammation and atherosclerosis in atrial fibrillation[J]. Curr Atherosclerosis Rep, 2017, 19(1): 2.
|
[5] |
PAMUKCU B, LIP GYH. Dronedarone as a new treatment option for atrial fibrillation patients: Pharmacokinetics, pharmacodynamics and clinical practice[J]. Exp Opin Pharm, 2011, 12: 131-140.
|
[6] |
GUO X, CHEN W, SUN H, et al. Kv1. 5 Inhibitors for treatment of atrial fibrillation: A tradeoff between selectivity and non-selectivity[J]. Curr Topics Med Chem, 2016, 16: 1843-1854.
|
[7] |
ANDUJAR I, RIOS JL, GINER RM, et al. Pharmacological properties of shikonin-a review of literature since 2002[J]. Planta Med, 2013, 79: 1685-1697.
|
[8] |
WANG S, ZHU Y, QIU R. Shikonin protects H9C2 cardiomyocytes against hypoxia/reoxygenation injury through activation of PI3K/Akt signaling pathway[J]. Biomed Pharm, 2018, 104: 712-717.
|
[9] |
YANG J, WANG Z, CHEN DL. Shikonin ameliorates isoproterenol (ISO)-induced myocardial damage through suppressing fibrosis, inflammation, apoptosis and ER stress[J]. Biomed Pharm, 2017, 93: 1343-1357.
|
[10] |
WANG XH, ZHANG JH, HU YN, et al. Effects of shikonin on apoptosis and oxidative stress of vascular endothelial cells induced by high glucose[J].Chin J Pathophysiol, 2018, 34: 1222-1227.
|
[11] |
WOZAKOWSKA-KAPON B. Changes in left atrial size in patients with persistent atrial fibrillation: A prospective echocardiographic study with a 5-year follow-up period[J]. Int J Cardiol, 2005, 101: 47-52.
|
[12] |
ZHANG YJ, MA N, SU F, et al. Increased TRPM6 expression in atrial fibrillation patients contribute to atrial fibrosis[J]. Exp Mol Pathol, 2015, 98: 486-490.
|
[13] |
MAENG YS, LEE GH, CHOI SI, et al. Histone methylation levels correlate with TGFBIp and extracellular matrix gene expression in normal and granular corneal dystrophy type 2 corneal fibroblasts[J]. BMC Med Genom, 2015, 8: 74.
|
[14] |
HARADA M, VAN WAGONER DR, NATTEL S. Role of inflammation in atrial fibrillation pathophysiology and management[J]. Circul J, 2015,79(3):495-502.
|
[15] |
WU N, XU B, XIANG Y, et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis[J]. Int J Cardiol, 2013, 169: 62-72.
|
[16] |
CONWAY DSG, BUGGINS P, HUGHES E, et al. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation[J]. Am Heart J, 2004, 148: 462-466.
|
[17] |
LI J, SOLUS J, CHEN Q, et al. Role of inflammation and oxidative stress in atrial fibrillation[J]. Heart Rhythm, 2010, 7: 438-444.
|
[18] |
YANG Y, WANG J, YANG Q, et al. Shikonin inhibits the lipopolysaccharide-induced release of HMGB1 in RAW264.7 cells via IFN and NF-κB signaling pathways[J]. Int Immunopharmacol, 2014, 19: 81-87.
|
[19] |
LU L, QIN A, HUANG H, et al. Shikonin extracted from medicinal Chinese herbs exerts anti-inflammatory effect via proteasome inhibition[J]. Eur J Pharmacol, 2011, 658: 242-247.
|